-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the phase III clinical study, the two RNA vaccines BNT162b2 and mRNA-1273 showed good preventive effects against new coronary pneumonia .
After the vaccine has been vaccinated in a large area, the effectiveness of these two vaccines in preventing symptomatic and asymptomatic new coronary pneumonia infection in real conditions is comparable to that of clinical trials .
Recently, researchers examined the effects of two RNA vaccines in the real world on reducing the risk of symptoms after infection, reducing viral load, and shortening the time for positive tests .
Recently, researchers have investigated the effects of two RNA vaccines in the real world.
The effect of reducing the risk of symptoms after infection, reducing the viral load and shortening the time to test positive
This prospective cohort study included 3975 healthy participants.
From December 14, 2020 to April 10, 2021, participants will undergo weekly nasal swab nucleic acid tests to evaluate the preventive effect of the vaccine
During the study period, 204 participants tested positive for nucleic acid (5%), of which 5 completed the vaccination (2 doses of vaccination over 14 days), and 11 partially completed the vaccination (14 days after the completion of the first vaccination, but the second Less than 14 days after the first vaccination), 156 people were not vaccinated
.
After completing the vaccination, the effective rate of the vaccine was 91%, and 81% after completing the partial vaccination
After completing the vaccination, the effective rate of the vaccine was 91%, and 81% after completing the partial vaccination
Real-world studies have shown that BNT162b2 and mRNA-1273, these two RNA vaccines, are effective in preventing new coronary pneumonia.
BNT162b2 and mRNA-1273, these two RNA vaccines are effective in preventing new coronary pneumonia.
Original source:
Mark G.
Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.
Leave a message here
